Abiopharma

MONOPAR THERAPEUTICS (MNPR) Announces Clinical Trial Update MONOPAR THERAPEUTICS (MNPR) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: treatments, year
• Diseases/Conditions: Monopar
• Collaboration: Monopar Therapeutics Inc.
  • We are grateful to the Wilson disease patients and their families whose experiences have informed our efforts to advance ALXN
  • ” Recent Program Developments ALXN1840 – NDA Submission Planned for Mid
  • 2026 for Wilson Disease Wilson disease is a rare genetic disorder characterized by impaired copper elimination, resulting in toxic accumulation in organs such as the liver and brain. ALXN1840 binds and mobilizes copper and has a novel mechanism of action as an albumin tripartite complex (“ATC”) activator that differentiates it from currently available first
    • Planned for Mid-2026